Literature DB >> 20375937

Pseudocirrhosis in metastatic esophageal cancer.

Chiharu Kobashigawa, Manabu Nakamoto, Akira Hokama, Tetsuo Hirata, Fukunori Kinjo, Jiro Fujita.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20375937     DOI： 10.1097/SMJ.0b013e3181d82d50

Source DB:  PubMed          Journal:  South Med J        ISSN： 0038-4348            Impact factor:   0.954


× No keyword cloud information.
  7 in total

1.  Pseudocirrhosis caused by regorafenib in an advanced rectal cancer patient with multiple liver metastases.

Authors:  Kensuke Kumamoto; Shungo Endo; Noriyuki Isohata; Azuma Nirei; Daiki Nemoto; Kenichi Utano; Takuro Saito; Kazutomo Togashi
Journal:  Mol Clin Oncol       Date:  2016-11-28

2.  Medullary thyroid cancer and pseudocirrhosis: case report and literature review.

Authors:  B L Harry; M L Smith; J R Burton; A Dasari; S G Eckhardt; J R Diamond
Journal:  Curr Oncol       Date:  2012-02       Impact factor: 3.677

3.  Pseudocirrhosis as a complication after chemotherapy for hepatic metastasis from breast cancer.

Authors:  Woo Kyoung Jeong; Seo-Youn Choi; Jinoo Kim
Journal:  Clin Mol Hepatol       Date:  2013-06

4.  Pseudocirrhosis: A Case Series and Literature Review.

Authors:  Abimbola Adike; Nina Karlin; Christine Menias; Elizabeth J Carey
Journal:  Case Rep Gastroenterol       Date:  2016-07-29

5.  Pseudocirrhosis of breast cancer metastases to the liver treated by chemotherapy.

Authors:  Su Lim Lee; Eun Deok Chang; Sae Jung Na; Jeong Soo Kim; Ho Jung An; Yoon Ho Ko; Hye Sung Won
Journal:  Cancer Res Treat       Date:  2014-01-15       Impact factor: 4.679

6.  Pseudocirrhosis in Gastric Cancer with Diffuse Liver Metastases after a Dramatic Response to Chemotherapy.

Authors:  Seiichiro Mitani; Shigenori Kadowaki; Hiroya Taniguchi; Hisanori Muto; Kei Muro
Journal:  Case Rep Oncol       Date:  2016-02-06

7.  Pseudocirrhosis in Breast Cancer - Experience From an Academic Cancer Center.

Authors:  Dharmesh Gopalakrishnan; Ain Shajihan; Andrei S Purysko; Jame Abraham
Journal:  Front Oncol       Date:  2021-07-02       Impact factor: 6.244
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.